Patent intelligence · US
US 8367105
Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage form…
Patent details — US 8367105
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 5, 2013
- Expiration
- Jan 31, 2033
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 15
- CPC classes
- A61K, A61K31/445, A61K31/55, A61K9/2059
Quick answer
US 8367105 (Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Feb 5, 2013. Expires Jan 31, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/445, A61K31/55, A61K9/2059, A61K9/2077, A61P
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Related coverage
Frequently asked questions
What is US patent 8367105?
US 8367105 (Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: granted. Granted Feb 5, 2013. Expires Jan 31, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8367105?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8367105 expire?
Our index shows an expiration date of Jan 31, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.